Aging is a multifactorial biological process characterized by a progressive decline in functional capacity at the molecular, cellular, tissue, and organismal levels. The aim of this review is to summarize current concepts of aging mechanisms and the prevention of age-related pathologies from a lymphological perspective, taking into account contemporary literature data and the results of our own studies. Currently, two major concepts dominate in gerontology: programmed aging, which considers aging as a genetically determined process, and damage accumulation theories, which associate aging with the progressive accumulation of molecular and cellular damage. The hallmarks of aging include genomic instability, telomere shortening, epigenetic alterations, impaired proteostasis and macroautophagy, dysregulation of nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, dysbiosis, hormonal imbalance, and disturbances in interstitial humoral transport and lymphatic outflow. At the tissue and organ levels, impairment of lymphatic drainage is of particular importance, leading to interstitial fluid stagnation and the accumulation of toxic metabolites, which exacerbate cellular and subcellular dysfunction. Phytotherapeutic agents containing flavonoids, phenolic compounds, terpenoids, glycosides, polysaccharides, and other biologically active substances exhibit antioxidant, anti-inflammatory, and cytoprotective properties. They inhibit lipid peroxidation, reduce excessive nitric oxide production, and contribute to the restoration of interstitial humoral transport and lymphatic outflow. Interstitial humoral transport and the lymphatic system, together with renal mechanisms, play key roles in maintaining body fluid homeostasis. Targeted regulation of lymphatic system function may help reduce tissue congestion, maintain physiological homeostasis, and improve quality of life in the elderly.

The aim of this study was to summarize current evidence on dust-related diseases of the bronchopulmonary system, medicinal plants, herbal formulations, and their underlying mechanisms of action. A literature review was conducted based on publications indexed in ScienceDirect, Google Scholar, SciFinder, Scopus, and Medline (PubMed), focusing on the mechanisms underlying dust-related diseases of the bronchopulmonary system, pneumoconiosis, and the potential of phytotherapeutic approaches to modulate these processes. The following keywords were used: bronchopulmonary system, pneumoconiosis, dust-related lung diseases, medicinal plants, herbal preparations, pulmonary rehabilitation, and lymphatic sanitation. The pathogenesis of pneumoconiosis involves the deposition of inhaled dust particles in the lung tissue, followed by chronic inflammation, oxidative stress, and progressive fibrosis. In experimental models, flavonoids, alkaloids, terpenoids, glycosides, tannins, and other phytochemical groups have demonstrated therapeutic potential in bronchopulmonary diseases. Among the compounds investigated, emodin, celastrol, kaempferol, sodium tanshinone IIA sulfonate, astragaloside IV, and dioscin have shown promising effects by modulating key signaling pathways and reducing inflammatory responses. Experimental evidence indicates that these phytochemicals can target major pathways involved in inflammation and fibrogenesis, thereby exerting antioxidant, anti-inflammatory, and antifibrotic effects. The lymphatic system also contributes to the pathogenesis of pneumoconiosis by transporting inhaled dust particles to regional lymph nodes, where their accumulation may promote lymph node sclerosis. Therefore, lymphatic sanitation may represent an important therapeutic mechanism of action of herbal formulations in pneumoconiosis. Our proposed lymphotropic herbal formulation enhances physiological lymphatic drainage and may positively influence the motility and functional activity of the tracheobronchial lymph nodes. The therapeutic potential of medicinal plants and herbal formulations in pneumoconiosis is supported by experimental findings for Tripterygium wilfordii (celastrol, through suppression of the EDNRB/Kng1–(endothelin receptor type B/kininogen1), Delphinium, Camellia, and Berberis species (kaempferol, through inhibition of TLR4 (Toll-like receptor 4 signaling), Astragalus membranaceus (astragaloside IV, through antifibrotic activity mediated by inhibition of the TGF-β1 (transforming growth factor beta 1)/Smad3 (SMAD family member 3) pathway), and Reynoutria japonica Houtt., Rheum, and Aloe species (emodin, through inhibition of Smad3 and NF-κB (nuclear factor kappa B) phosphorylation and reduction of TGF-β1, α-SMA (alpha-smooth muscle actin), collagen I, TNF-α (tumor necrosis factor alpha), and IL-1β (interleukin-1 beta) levels in lung tissue). For these and several other medicinal plants and their flavonoids, antifibrotic activity has been demonstrated through inhibition of the Akt/NF-κB (protein kinase B/nuclear factor kappa B) signaling pathway. A promising direction for future research is to evaluate the combined use of herbal formulations with established antifibrotic agents to determine whether synergistic therapeutic effects can be achieved.